```
     (FILE 'HOME' ENTERED AT 17:47:01 ON 09 MAY 2001)

     FILE 'REGISTRY' ENTERED AT 17:47:18 ON 09 MAY 2001
L1            32 S ILLLKVAG/SQSP
L2             1 S ILLLKVAG/SQEP

     FILE 'CAPLUS' ENTERED AT 17:47:47 ON 09 MAY 2001
L3             2 S L2
L4            28 S L1

     FILE 'REGISTRY' ENTERED AT 17:52:06 ON 09 MAY 2001
L5             1 S 94219-00-8
L6             2 S L1 AND SQL<11

     FILE 'CAPLUS, TOXLIT' ENTERED AT 17:52:44 ON 09 MAY 2001
L7             3 S L6
L8             2 DUP REM L7 (1 DUPLICATE REMOVED)

     FILE 'REGISTRY' ENTERED AT 17:53:12 ON 09 MAY 2001
L9             1 S LRILLLGV/SQEP
L10            1 S LGILLLKV/SQEP
L11            1 S ILLGKATLY/SQEP
L12            1 S MGLRILLL/SQEP
L13            1 S LLMTLRLWSS/SQEP

     FILE 'CAPLUS, TOXLIT, USPATFULL' ENTERED AT 17:55:34 ON 09 MAY 2001
L14            6 S L9-L13
L15            5 DUP REM L14 (1 DUPLICATE REMOVED)

     FILE 'REGISTRY' ENTERED AT 17:58:23 ON 09 MAY 2001
L16            1 S IIVTDVIATL/SQEP
L17            1 S IVIVDICIT/SQEP
L18            1 S FLFAEIVSI/SQEP
L19            1 S AGFNLLMT/SQEP
L20            1 S YGRADCGITS/SQEP
L21            1 S YGRADCGITS/SQSP
L22            1 S WGRADCGITS/SQEP
L23            1 S YGRADCITS/SQEP
L24            1 S SSDVPCDATLT/SQEP

     FILE 'CAPLUS, TOXLIT, USPATFULL' ENTERED AT 18:00:43 ON 09 MAY 2001
L25            1 S L16-L24

     FILE 'REGISTRY' ENTERED AT 18:02:25 ON 09 MAY 2001
L26            0 S (LVIMFYW){2-10}[KHR]/SQSP
L27       162289 S [LVIMFYW][LVIMFYW][KHR][LVIMFYW][LVIMFYW]/SQSP
L28            0 S L27AND SQL=5
L29        53693 S [LVIMFYW]{LVIMFYW][LVIMFYW][KHR][LVIMFYW][LVIMFYW]/SQSP
L30        53693 S [LVIMFYW]{LVIMFYW][LVIMFYW][KHR][LVIMFYW][LVIMFYW]/SQSP
L31           22 S L30 AND SQL=6

     FILE 'CAPLUS, USPATFULL' ENTERED AT 18:07:15 ON 09 MAY 2001
L32           65 S L31
L33           58 DUP REM L32 (7 DUPLICATES REMOVED)

     FILE 'REGISTRY' ENTERED AT 18:08:38 ON 09 MAY 2001
L34        52766 S [LVIMFYW][LVIMFYW][LVIMFYW][ED][LVIMFYW][LVIMFYW]/SQSP
L35           22 S L34 AND SQL=6
```

FILE 'CAPLUS, USPATFULL' ENTERED AT 18:09:28 ON 09 MAY 2001

L36 14 S L35

L37 14 DUP REM L36 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 18:11:44 ON 09 MAY 2001

L38 0 S 107041-06-5/SQIDE

L40 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2001 ACS
AN 1987:100588 CAPLUS
DN 106:100588
TI Inhibition of phosphorylcholine binding to antibodies using synthetic peptides
AU Lai, Eric H. C.; Kabat, Elvin A.; Meienhofer, Johannes; Heimer, E. P.; Olson, Arthur J.; Lerner, Richard
CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
SO Nature (London) (1987), 325(7000), 168-71
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English
CC 15-3 (Immunochemistry)
AB The amino-acid sequence Phe-Tyr-Met-Glu is unique to phosphorylcholine (PC)-binding antibodies. This unique tetrapeptide seems to be involved in PC binding. The effectiveness of Phe-Tyr-Met-Glu and other structurally related peptides in inhibiting the binding of PC to PC-binding proteins McPC603 and HOPC8 was compared. Also, a surface-simulation peptide that was constructed to mimic the combining site of McPC603 was tested. Apparently, all these peptides inhibit the binding of PC to PC-binding proteins non-specifically. It was shown by computer modeling that the surface-simulation peptide does not duplicate the combining site of McPC603.
ST phosphorylcholine peptide antibody binding
IT Process simulation, biological
(of phosphorylcholine-binding protein binding to surface-simulation peptide)
IT Peptides, biological studies
RL: BIOL (Biological study)
(phosphorylcholine binding to antibodies inhibition by)
IT Antibodies
RL: BIOL (Biological study)
(phosphorylcholine binding to, inhibition of, by synthetic peptides)
IT Proteins, specific or class
RL: BIOL (Biological study)
(phosphorylcholine-binding, Igs, peptide inhibition of binding by)
IT 107-73-3, Phosphorylcholine
RL: BIOL (Biological study)
(antibodies binding to, inhibition of, by synthetic peptides)
IT 62-49-7 563-24-6, Glycerol phosphorylcholine 58569-55-4, Met-enkephalin 58822-25-6 69871-75-6 79942-99-7 89755-21-5 107041-02-1 107041-03-2 107041-04-3 107041-05-4 **107041-06-5** 107041-07-6
RL: BIOL (Biological study)

L37 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 2000:455708 CAPLUS
DN 133:187583
TI Structure-activity studies of reduced-size gonadotropin-releasing hormone agonists derived from the sequence of an endothelin antagonist
AU Yahalom, Dror; Rahimipour, Shai; Koch, Yitzhak; Ben-Aroya, Nurit; Fridkin, Mati
CS Departments of Organic Chemistry and Neurobiology, Weizmann Institute of Science, Rehovot, 76100, Israel
SO J. Med. Chem. (2000), 43(15), 2824-2830
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT **289653-43-6**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity studies of reduced-size gonadotropin-releasing hormone agonists derived from sequence of endothelin antagonist)
RN 289653-43-6 CAPLUS
CN Cyclo(L-.alpha.-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophyl-D-tryptophyl-L-leucyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 22
RE
(2) Bernatowicz, M; Anal Biochem 1986, V155, P95 CAPLUS
(3) Burgus, R; Proc Natl Acad Sci U S A 1972, V69, P278 CAPLUS
(4) Cody, W; J Med Chem 1995, V38, P2809 CAPLUS
(5) Daane, T; Endocrinology 1971, V88, P653 CAPLUS
(6) Doherty, A; J Med Chem 1993, V36, P2585 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 2001:8549 CAPLUS
DN 134:208114
TI Synthesis of N-4909 analogs Part I. A stimulant of apolipoprotein E secretion in human hepatoma G2 cells
AU Yanai, Makoto; Suzuki, Masashi; Kawamura, Kouji; Oshida, Norio; Hiramoto, Shigeru; Yasuda, Orie; Shingai, Akiko; Suguro, Toshio
CS 1st Pharmaceutical Laboratory, Pharmaceutical Research Laboratories, Nisshin Flour Milling Co., Ltd., Saitama, 356-8511, Japan
SO J. Antibiot. (2000), 53(12), 1385-1396
CODEN: JANTAJ; ISSN: 0021-8820
PB Japan Antibiotics Research Association
DT Journal
LA English
IT **201039-90-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of N-4909 analogs as stimulants of apolipoprotein E secretion in human hepatoma G2 cells)
RN 201039-90-9 CAPLUS
CN L-Isoleucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucyl-D-leucyl-L-valyl-L-.alpha.-aspartyl-D-leucyl-, 4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RE.CNT 6
RE
(1) Hiramoto, S; J Antibiotics 1996, V49, P949 CAPLUS
(2) Mahley, R; J Clin Invest 1989, V83, P2125 CAPLUS

(3) Suguro, T; J Antibiotics 1999, V52, P835 CAPLUS
(4) Yamada, N; J Clin Invest 1992, V89, P706 CAPLUS
(5) Yamada, N; Proc Natl Acad Sci 1989, V86, P665 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 2000:187698 CAPLUS
DN 132:317436
TI Chromatographic resolution of tryptophan enantiomers with L-Leu-L-Leu-L-Leu peptide. Effects of mobile phase composition and chromatographic support
AU Kaufman, D. B.; Hayes, T.; Buettner, J.; Hammond, D. J.; Carbonell, R. G.
CS Department of Chemical Engineering, North Carolina State University, Raleigh, NC, USA
SO J. Chromatogr., A (2000), 874(1), 21-26
CODEN: JCRAEY; ISSN: 0021-9673
PB Elsevier Science B.V.
DT Journal
LA English
IT **265112-93-4D**, reaction product with polystyrene
RL: ARU (Analytical role, unclassified); NUU (Nonbiological use, unclassified); PRP (Properties); ANST (Analytical study); USES (Uses)
(effects of mobile phase compn. and leucine peptide contg. chromatog. support on chromatog. resoln. of tryptophan enantiomers)
RN 265112-93-4 CAPLUS
CN L-Leucine, L-leucyl-L-leucyl-L-leucyl-L-.alpha.-glutamyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 10
RE
(1) Baczuk, R; J Chromatogr 1971, V60, P351 CAPLUS
(2) Buettner, J; Int J Peptide Protein Res 1996, V47, P70 CAPLUS
(4) Ihara, T; J Chromatogr A 1995, V694, P49 CAPLUS
(5) Knox, J; J Chromatogr 1981, V218, P341 CAPLUS
(6) Knox, J; J Chromatogr 1982, V234, P222 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 4 OF 14 USPATFULL
AN 1999:33978 USPATFULL
TI Cyclic endothelin antagonists
IN Wakimasu, Mitsuhiro, Ibaraki, Japan

Kikuchi, Takashi, Ibaraki, Japan
Kawada, Akira, Ibaraki, Japan
Shirafuji, Hideo, Kyoto, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5883075 19990316
AI US 1996-680534 19960709 (8)
RLI Division of Ser. No. US 1994-231449, filed on 20 Apr 1994, now patented,
Pat. No. US 5616684 which is a continuation of Ser. No. US 1992-927205, filed on 7 Aug 1992, now abandoned
PRAI JP 1991-203032 19910813
JP 1991-303635 19911119
JP 1992-35435 19920221
JP 1992-111792 19920430
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Wessendorf, T. D.
LREP Conlin, David G.; Neuner, George W.; Lowen, Cara Z.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1,12
DRWN No Drawings
LN.CNT 4813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **150209-99-7P**
(prepn. of, as endothelin and neurokinin antagonist)
RN 150209-99-7 USPATFULL
CN Cyclo(D-.alpha.-aspartyl-L-tryptophyl-L-leucyl-D-leucyl-L-leucyl-D-tryptophyl) (9CI) (CA INDEX NAME)




L37 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1998:42417 CAPLUS
DN 128:102397
TI Preparation of cyclic depsipeptides as apolipoprotein E production promoters
IN Yanai, Makoto; Suzuki, Masashi; Oshida, Norio; Kawamura, Koji; Hiramoto, Shigeru; Yasuda, Orie; Kinoshita, Nobuhiro; Shingai, Akiko; Kanai, Masako
PA Nisshin Flour Milling Co., Ltd., Japan; Yanai, Makoto; Suzuki, Masashi; Oshida, Norio; Kawamura, Koji; Hiramoto, Shigeru; Yasuda, Orie; Kinoshita, Nobuhiro; Shingai, Akiko; Kanai, Masako
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

| | | | | | |
|---|---|---|---|---|---|
| PI | WO 9749724 | A1 | 19971231 | WO 1997-JP2194 | 19970625 |
| | W: CA, JP, KR, US | | | | |
| | RW: CH, DE, FR, GB, IT, NL | | | | |
| | CA 2258487 | AA | 19971231 | CA 1997-2258487 | 19970625 |
| | EP 967222 | A1 | 19991229 | EP 1997-928461 | 19970625 |
| | R: CH, DE, FR, GB, IT, LI, NL | | | | |
| PRAI | JP 1996-164317 | | 19960625 | | |
| | JP 1996-271321 | | 19960924 | | |
| | WO 1997-JP2194 | | 19970625 | | |

OS MARPAT 128:102397

IT **201039-90-9P 201040-29-1P 201040-48-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of cyclic depsipeptides as apolipoprotein E and A1 prodn. promoters for treatment of dementia and hyperlipemia)

RN 201039-90-9 CAPLUS

CN L-Isoleucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucyl-D-leucyl-L-valyl-L-.alpha.-aspartyl-D-leucyl-, 4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 201040-29-1 CAPLUS

CN L-Isoleucine, L-leucyl-L-leucyl-L-valyl-L-.alpha.-aspartyl-D-leucyl-, 4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201040-48-4 CAPLUS
CN L-Isoleucine, L-leucyl-L-leucyl-L-valyl-L-.alpha.-aspartyl-L-leucyl-, 4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1997:805891 CAPLUS
DN 128:57436
TI A method for selecting target pathogen-inhibiting substances, and test kits for use therein
IN Lankinen, Hilkka; Heiskanen, Tuomas; Vaheri, Antti; Lundkvist, Ake
PA Helsinki University Licensing Ltd., Finland; Lankinen, Hilkka; Heiskanen, Tuomas; Vaheri, Antti; Lundkvist, Ake
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9745743 | A1 | 19971204 | WO 1997-FI339 | 19970530 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,

GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| | FI 9602269 | A | 19971201 | FI 1996-2269 | 19960530 |
| | AU 9729650 | A1 | 19980105 | AU 1997-29650 | 19970530 |
| PRAI | FI 1996-2269 | | 19960530 | | |
| | WO 1997-FI339 | | 19970530 | | |

IT **200351-45-7**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for selecting target pathogen-inhibiting substances, and test kits)
RN 200351-45-7 CAPLUS
CN L-Tryptophan, L-tryptophyl-L-tyrosyl-L-phenylalanyl-L-.alpha.-aspartyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L37 ANSWER 7 OF 14 USPATFULL
AN 97:27269 USPATFULL
TI Cyclic peptides and use thereof
IN Wakimasu, Mitsuhiro, Ibaraki, Japan
Kikuchi, Takashi, Ibaraki, Japan
Kawada, Akira, Ibaraki, Japan
Shirafuji, Hideo, Kyoto, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5616684 19970401
AI US 1994-231449 19940420 (8)
RLI Continuation of Ser. No. US 1992-927205, filed on 7 Aug 1992, now abandoned
PRAI JP 1991-203032 19910813
JP 1991-303635 19911119
JP 1992-35436 19920221

JP 1992-111792 19920430
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Wessendorf, T.
D.
LREP Conlin, David G.; Neuner, George W.; Lowen, Cara Z.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4778
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **150209-99-7P**
(prepn. of, as endothelin and neurokinin antagonist)
RN 150209-99-7 USPATFULL
CN Cyclo(D-.alpha.-aspartyl-L-tryptophyl-L-leucyl-D-leucyl-L-leucyl-D-tryptophyl) (9CI) (CA INDEX NAME)




L37 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1995:665446 CAPLUS
DN 123:75073
TI Structure-activity relationships of the potent combined endothelinA/endothelinB receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21 (PD 142893): development of endothelinB receptor selective antagonists
AU Cody, Wayne L.; He, John X.; DePue, Patricia L.; Waite, Lisa A.; Leonard, Daniele M.; Sefler, Andrea M.; Kaltenbronn, James S.; Haleen, Stephen J.; Walker, Donnelle M.; et al.
CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SO J. Med. Chem. (1995), 38(15), 2809-19
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
IT **165329-39-5 165329-40-8**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(structure-activity relationships of the potent combined ETA/ETB receptor antagonist PD 142893)
RN 165329-39-5 CAPLUS
CN Cyclo(L-.alpha.-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophyl-D-phenylalanyl-L-leucyl) (9CI) (CA INDEX NAME)



RN 165329-40-8 CAPLUS
CN Cyclo(L-.alpha.-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophyl-.beta.-phenyl-D-phenylalanyl-L-leucyl) (9CI) (CA INDEX NAME)



L37 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1995:624467 CAPLUS
DN 123:329232
TI A new endothelin antagonist lipopeptide isolated from the strain of Bacillus subtilis
AU Ohshima, Takeshi; Tamura, Masahiro; Oda, Toshiaki; Hirata, Mitsuteru; Shiratsuchi, Masami; Hamada, Masa; Maeda, Kenji; Takeuchi, Tomio
CS Tokyo Research Laboratories, Kowa Co., Ltd., Higashimurayama, 189, Japan
SO Pept. Chem. (1995), Volume Date 1994, 32nd, 33-6
CODEN: PECHDP; ISSN: 0388-3698
DT Journal
LA English
IT **166034-90-8**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new endothelin antagonist lipopeptide isolated from the strain of Bacillus subtilis in relation to structure-activity relations of synthetic peptides)
RN 166034-90-8 CAPLUS
CN L-Isoleucine, N-[N-[N-[N-[N-(N-acetyl-L-leucyl)-D-leucyl]-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-tetradecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1994:245777 CAPLUS
DN 120:245777
TI Cyclic peptides and use thereof
IN Wakimasu, Mitsuhiro; Kikuchi, Takashi; Kawada, Akira; Shirahuji, Hideo
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 88 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 552417 | A1 | 19930728 | EP 1992-117182 | 19921008 |
| | EP 552417 | B1 | 19990707 | | |
| | R: ES, GR | | | | |
| | JP 06009689 | A2 | 19940118 | JP 1992-216019 | 19920813 |
| | ES 2133295 | T3 | 19990916 | ES 1992-117182 | 19921008 |
| | US 5616684 | A | 19970401 | US 1994-231449 | 19940420 |
| | US 5883075 | A | 19990316 | US 1996-680534 | 19960709 |
| PRAI | JP 1991-303635 | | 19911119 | | |
| | JP 1992-35436 | | 19920221 | | |
| | JP 1992-111792 | | 19920430 | | |
| | JP 1992-216019 | | 19920813 | | |
| | JP 1991-203032 | | 19910813 | | |
| | JP 1992-35435 | | 19920221 | | |
| | US 1992-927205 | | 19920807 | | |
| | US 1994-231449 | | 19940420 | | |

OS MARPAT 120:245777
IT **150209-99-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and endothelin and NK2 antagonist activity)
RN 150209-99-7 CAPLUS
CN Cyclo(D-.alpha.-aspartyl-L-tryptophyl-L-leucyl-D-leucyl-L-leucyl-D-tryptophyl) (9CI) (CA INDEX NAME)



L37 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1993:603860 CAPLUS
DN 119:203860
TI Preparation of cyclic peptides as endothelin and neurokinin antagonists
IN Wakimasu, Mitsuhiro; Kikuchi, Takashi; Kawada, Akira; Shirahuji, Hideo
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 88 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 528312 | A2 | 19930224 | EP 1992-113568 | 19920808 |
| | EP 528312 | A3 | 19930414 | | |
| | EP 528312 | B1 | 19970716 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | AT 155486 | E | 19970815 | AT 1992-113568 | 19920808 |
| | ES 2103857 | T3 | 19971001 | ES 1992-113568 | 19920808 |
| | CA 2075878 | AA | 19930214 | CA 1992-2075878 | 19920812 |
| | NO 9203142 | A | 19930215 | NO 1992-3142 | 19920812 |
| | US 5616684 | A | 19970401 | US 1994-231449 | 19940420 |
| | JP 08225595 | A2 | 19960903 | JP 1995-342625 | 19951228 |
| | JP 2726647 | B2 | 19980311 | | |
| | US 5883075 | A | 19990316 | US 1996-680534 | 19960709 |
| PRAI | JP 1991-203032 | | 19910813 | | |
| | JP 1991-303635 | | 19911119 | | |
| | JP 1992-35436 | | 19920221 | | |
| | JP 1992-111792 | | 19920430 | | |
| | JP 1992-35435 | | 19920221 | | |
| | US 1992-927205 | | 19920807 | | |
| | US 1994-231449 | | 19940420 | | |

OS MARPAT 119:203860
IT **150209-99-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as endothelin and neurokinin antagonist)
RN 150209-99-7 CAPLUS
CN Cyclo(D-.alpha.-aspartyl-L-tryptophyl-L-leucyl-D-leucyl-L-leucyl-D-tryptophyl) (9CI) (CA INDEX NAME)



L37 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1987:100588 CAPLUS
DN 106:100588
TI Inhibition of phosphorylcholine binding to antibodies using synthetic peptides
AU Lai, Eric H. C.; Kabat, Elvin A.; Meienhofer, Johannes; Heimer, E. P.; Olson, Arthur J.; Lerner, Richard
CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
SO Nature (London) (1987), 325(7000), 168-71
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English
IT **107041-06-5**
RL: BIOL (Biological study)
(phosphorylcholine binding to antibodies inhibition by)
RN 107041-06-5 CAPLUS
CN L-Valine, N-[N-[N-[N-(N-L-phenylalanyl-L-tyrosyl)-L-methionyl]-L-.alpha.-glutamyl]-L-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1979:104342 CAPLUS
DN 90:104342
TI Antibacterial peptide derivatives. Part III. Synthesis of new 3-hydroxyacyl heptapeptides of potential tuberculostatic activity
AU Neugebauer, Witold; Lammek, Bernard; Perkowska, Danuta; Kupryszewski, Gotfryd
CS Inst. Chem., Univ. Gdansk, Gdansk, Pol.
SO Pol. J. Chem. (1978), 52(7-8), 1435-45

CODEN: PJCHDQ
DT Journal
LA English
IT **66544-14-7P 68838-98-2P 68839-04-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and partial deblocking of)
RN 66544-14-7 CAPLUS
CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-L-leucyl]-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B







RN 68838-98-2 CAPLUS
CN L-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-L-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68839-04-3 CAPLUS
CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-D-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **68838-99-3P 68839-05-4P 68839-06-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling of, with glutamic acid deriv.)
RN 68838-99-3 CAPLUS
CN D-Leucine,
N-[N-[N-[N-(N-D-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68839-05-4 CAPLUS
CN D-Leucine,
N-[N-[N-[N-(N-L-leucyl-D-leucyl)-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68839-06-5 CAPLUS
CN D-Leucine,
N-[N-[N-[N-(N-L-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L37 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 1978:406543 CAPLUS
DN 89:6543
TI Tuberculostatic 3-hydroxyacyl heptapeptides
AU Kupryszewski, Gotfryd; Lammek, Bernard; Neugebauer, Witold
CS Inst. Chem., Univ. Gdansk, Gdansk, Pol.
SO Pept., Proc. Am. Pept. Symp., 5th (1977), 218-20. Editor(s): Goodman, Murray; Meienhofer, Johannes. Publisher: Wiley, New York, N. Y. CODEN: 37OBAT
DT Conference
LA English
IT **66544-14-7P 66544-31-8P 66544-32-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deblocking of)
RN 66544-14-7 CAPLUS
CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-L-leucyl]-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 66544-31-8 CAPLUS
CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-D-leucyl]-L-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.











RN 66544-32-9 CAPLUS
CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-D-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







IT **66544-15-8P 66544-33-0P 66544-34-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with hydroxyacylglutamic acid deriv.)
RN 66544-15-8 CAPLUS
CN D-Leucine,
N-[N-[N-[N-(N-L-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66544-33-0 CAPLUS
CN D-Leucine,
N-[N-[N-[N-(N-D-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 66544-34-1 CAPLUS
CN D-Leucine,
N-[N-[N-[N-(N-L-leucyl-D-leucyl)-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 1 OF 5 USPATFULL
AN 2000:54077 USPATFULL
TI Peptide
IN Manolios, Nicholas, Kensington, Australia
PA Northern Sydney Area Health Service of Pacific Highway, St. Leonards, Australia (non-U.S. corporation)
PI US 6057294 20000502
WO 9622306 19960725
AI US 1997-875013 19970915 (8)
WO 1996-AU18 19960116
19970915 PCT 371 date
19970915 PCT 102(e) date
PRAI AU 1995-950589 19950116
AU 1995-950590 19950116
DT Utility
EXNAM Primary Examiner: Jones, Dwayne C.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Needle & Rosenberg, P.C.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180994-66-5P**
(peptides which effect T-cells for treatment of inflammatory or autoimmune diseases)
RN 180994-66-5 USPATFULL
CN L-Leucine, L-methionylglycyl-L-leucyl-L-arginyl-L-isoleucyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 136 OF 164 CAPLUS COPYRIGHT 2001 ACS
AN 1995:858555 CAPLUS
DN 124:30418
TI Peptide capable of inducing immune response against HIV and AIDS preventive or remedy containing the peptide
IN Takiguchi, Masafumi; Miwa, Kiyoshi
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9511255 | A1 | 19950427 | WO 1994-JP1756 | 19941019 |
| | W: AU, CA, CN, JP, KR, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2173138 | AA | 19950427 | CA 1994-2173138 | 19941019 |
| | AU 9479487 | A1 | 19950508 | AU 1994-79487 | 19941019 |
| | AU 685521 | B2 | 19980122 | | |
| | EP 728764 | A1 | 19960828 | EP 1994-930335 | 19941019 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | CN 1133597 | A | 19961016 | CN 1994-193851 | 19941019 |
| | CN 1055701 | B | 20000823 | | |
| | US 5756666 | A | 19980526 | US 1996-615181 | 19960404 |
| PRAI | JP 1993-261302 | A | 19931019 | | |
| | WO 1994-JP1756 | W | 19941019 | | |

AB This invention relates to (1) a peptide which is a fragment of the whole protein of HIV, the fragment having a sequence of 8 to 11 consecutive amino acid residues, corresponds to an human leukocyte antigen (HLA)-binding motif, is in fact bound to HLA, and can induce a killer cell that targets HIV-infected cells, (2) DNA which codes said peptide, (3) a method for sampling said peptide which involves (a) synthesis of peptides contg. a sequence of 8 to 11 consecutive amino acid residues (fragments of the whole protein of HIV) and corresponding to an HLA-binding motif, (b) selecting peptides actually binding to HLA among these synthetic peptides, and (c) further sampling peptides binding to a HLA class I antigen for stimulating a peripheral lymphocyte of a HIV-diseased patient and inducing a killer cell that specifically targets HIV-infected cells, and (4) an AIDS preventive or remedy contg. said peptide. This peptide induces cell-mediated immunity against HIV. Thus, 58 peptides matching the motif of HLA-B* 3501-binding autoantigen peptide were selected from whole protein sequence of ARV-2 HIV, synthesized by a Shimazu peptide synthesizer, and subjected to the binding test using genetically engineered RMA-S-B* 3501 cells that expresses HLA-B* 3501 antigen. Among these peptides, 26 peptides showed high, medium, and low binding affinity to HLA-B* 3501 antigen. For example, HIV(B35)-3 (nef 133-139) TPGPGIRY, HIV(B35)-14 NPDIVIYQY (I), and HIV(B35)ARV2-8 FPVRPQVPL (II) showed high binding affinity, while HIV(B35)-16 (pol 574-582) TPPLVKLWY (III), HIV(B35)-18 (pol 577-596) EPIVGAETFY (IV), and HIV(B35)POL-20 (pol 311-319) SPAIFQSSM (V) had medium binding affinity. In an assay using genetically engineered T2-B* 3501 cells contg. HLA-B* genes as the target cells, 13 of 26 HLA-B* 3501-binding peptides, including I - IV, were

effective for inducing cytotoxic **T-cells** from lymphocytes of HIV-infected patients having cytotoxic **T cell**-inducing HLA-B* 3501. Cytotoxic **T cell** -inducing peptides of whole protein sequences of MN, NDK, HXB-2, and SF-2 HIV were similarly obtained.

ST peptide prepn immunity HIV; human leukocyte antigen binding motif; killer cell; target HIV infected cell; AIDS **treatment** peptide; whole protein fragment HIV

IT 111364-12-6P 135861-46-0P 153045-53-5P 157896-38-3P 165898-55-5P
169034-14-4P 169034-17-7P 169034-19-9P 169034-20-2P 169034-21-3P
169034-68-8P 169034-69-9P 169034-70-2P 169034-71-3P 169034-72-4P
169034-73-5P 169034-74-6P 169034-75-7P 169034-76-8P 169034-77-9P
169034-78-0P 169034-79-1P 169034-80-4P 169034-81-5P 169034-82-6P
169034-83-7P 169034-84-8P 169034-85-9P 169034-86-0P 169034-87-1P
**169034-88-2P** 169034-89-3P
RL: BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(prepn. of HIV whole protein-related peptides and binding affinity to human leukocyte antigen)

IT 135993-84-9P 169033-88-9P **169033-89-0P** 169033-90-3P
169033-91-4P 169033-92-5P 169033-93-6P 169033-94-7P 169033-95-8P
169033-96-9P 169033-97-0P 169033-98-1P 169033-99-2P 169034-00-8P
169034-01-9P 169034-02-0P 169034-03-1P 169034-04-2P
**169034-05-3P** 169034-06-4P 169034-07-5P 169034-08-6P
169034-09-7P 169034-10-0P **169034-11-1P** 169034-12-2P
169034-13-3P 169034-14-4P 169034-15-5P 169034-16-6P 169034-17-7P
169034-18-8P 169034-19-9P 169034-20-2P 169034-21-3P 169034-22-4P
169034-23-5P 169034-24-6P **169034-25-7P** 169034-26-8P
169034-27-9P 169034-28-0P 169034-29-1P 169034-30-4P 169034-31-5P
169034-32-6P 169034-33-7P 169034-34-8P 169034-35-9P 169034-36-0P
169034-37-1P 169034-38-2P 169034-39-3P 169034-40-6P 169034-41-7P
169034-42-8P 169034-43-9P 169034-44-0P 169034-45-1P 169034-46-2P
169034-47-3P 169034-48-4P 169034-49-5P 169034-50-8P 169034-51-9P
169034-52-0P 169034-53-1P 169034-54-2P 169034-55-3P 169034-56-4P
169034-57-5P 169034-58-6P 169034-59-7P 169034-60-0P 169034-61-1P
169034-62-2P 169034-63-3P 169034-64-4P 169034-65-5P
**169034-66-6P** 169034-67-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of HIV whole protein-related peptides for inducing cell-mediated immune response against HIV and AIDS preventive or remedy)

IT **169034-88-2P**
RL: BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(prepn. of HIV whole protein-related peptides and binding affinity to human leukocyte antigen)

RN 169034-88-2 CAPLUS

CN L-Phenylalanine, N-[N-[N-[N-[N-[N-(1-L-.alpha.-aspartyl-L-prolyl)-L-.alpha.-glutamyl]-L-isoleucyl]-L-valyl]-L-methionyl]-L-histidyl]-L-seryl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **169033-89-0P 169034-05-3P 169034-11-1P**
**169034-25-7P 169034-66-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of HIV whole protein-related peptides for inducing cell-mediated immune response against HIV and AIDS preventive or remedy)

RN 169033-89-0 CAPLUS

CN L-Tyrosine,
L-asparaginyl-L-prolyl-L-.alpha.-aspartyl-L-isoleucyl-L-valyl-
L-isoleucyl-L-tyrosyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 169034-05-3 CAPLUS
CN L-Tyrosine, N-[N-[N-[N-[N-(1-L-.alpha.-glutamyl-L-prolyl)-L-valyl]-L-histidyl]-L-.alpha.-glutamyl]-L-valyl]-L-tyrosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









RN 169034-11-1 CAPLUS
CN L-Leucine,
L-.alpha.-aspartyl-L-prolyl-L-asparaginyl-L-prolyl-L-glutaminyl-L-.alpha.-glutamyl-L-valyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 169034-25-7 CAPLUS
CN L-Isoleucine, N-[N-[N-[N-[N-[N-(1-L-isoleucyl-L-prolyl)-L-threonyl]-L-seryl]glycyl]-L-.alpha.-aspartyl]-L-valyl]-L-valyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 169034-66-6 CAPLUS
CN L-Tyrosine,
L-asparaginyl-L-prolyl-L-.alpha.-glutamyl-L-isoleucyl-L-valyl-
L-isoleucyl-L-tyrosyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN **169034-25-7** REGISTRY
CN L-Isoleucine, N-[N-[N-[N-[N-[N-(1-L-isoleucyl-L-prolyl)-L-threonyl]-L-seryl]glycyl]-L-.alpha.-aspartyl]-L-valyl]-L-valyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9

SEQ 1 IPTSGDVVI
MF C40 H69 N9 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1994:52437 CAPLUS
DN 120:52437
TI Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis
AU Malcherek, Georg; Falk, Kirsten; Roetzschke, Olaf; Rammensee, Hans Georg; Stevanovic, Stefan; Gnau, Volker; Jung, Juenther; Melms, Arthur
CS Neurol. Klin, Univ. Tuebingen, Tuebingen, Germany
SO Int. Immunol. (1993), 5 1229-37
CODEN: INIMEN; ISSN: 0953-8178
DT Journal
LA English

L15 ANSWER 77 OF 88 CAPLUS COPYRIGHT 2002 ACS
AN 1994:577174 CAPLUS
DN 121:177174
TI Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1
AU Tsomides, Theodore J.; Aldovini, Anna; Johnson, R. Paul; Walker, Bruce D.; Young, Richard A.; Eisen, Herman N.
CS Cent. Cancer Res., Massachusetts Inst. Technol., Cambridge, MA, 02139, USA
SO J. Exp. Med. (1994), 180(4), 1283-93
CODEN: JEMEAV; ISSN: 0022-1007
DT Journal
LA English
IT **139079-41-7**
RL: BIOL (Biological study)
(of reverse transcriptase of HIV-1 virus, as naturally processed epitope for cytotoxic T-cells)

L18 ANSWER 155 OF 164 CAPLUS COPYRIGHT 2001 ACS
AN 1991:677941 CAPLUS
DN 115:277941
TI An assay for direct binding of peptides that are **T-cell** epitopes to MHC gene products on intact antigen-presenting cells and the use thereof for screening susceptibility to autoimmune diseases
IN Mozes, Edna; Pecht, Israel
PA Yeda Research and Development Co., Ltd., Israel
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI EP 432691 | A1 | 19910619 | EP 1990-123692 | 19901210 |
| R: CH, DE, DK, FR, GB, IT, LI, SE | | | | |
| PRAI IL 1989-92629 | A | 19891210 | | |

IT **137715-47-0D**, biotinylated
RL: BIOL (Biological study)
(myasthenia gravis screening and **treatment** with)
RN 137715-47-0 CAPLUS
CN L-Valine,
L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-valyl-L-.alpha.-glutamyl-
L-leucyl-L-isoleucyl-L-prolyl-L-seryl-L-threonyl-L-seryl-L-seryl-L-alanyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.













IT **137715-47-0 137732-20-8**
RL: BIOL (Biological study)
(myasthenia gravis **treatment** with pharmaceutical compns. contg.)
RN 137715-47-0 CAPLUS
CN L-Valine,
L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-valyl-L-.alpha.-glutamyl-
L-leucyl-L-isoleucyl-L-prolyl-L-seryl-L-threonyl-L-seryl-L-seryl-L-alanyl-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 137732-20-8 CAPLUS

CN L-Valine, L-valyl-L-isoleucyl-L-valyl-L-.alpha.-glutamyl-L-leucyl-L-isoleucyl-L-prolyl-L-seryl-L-threonyl-L-seryl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

V I V (α E) L I P S T S S A V

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



L16 ANSWER 139 OF 164 CAPLUS COPYRIGHT 2001 ACS
AN 1995:314564 CAPLUS
DN 122:103468
TI Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles
AU Celis, Esteban; Fikes, John; Wentworth, Peggy; Sidney, John; Southwood, Scott; Maewal, Ajesh; Del Guercio, Marie-France; Sette, Alessandro; Livingston, Brian
CS Cytel Corporation, San Diego, CA, 92121, USA
SO Mol. Immunol. (1994), 31(18), 1423-30
CODEN: MOIMD5; ISSN: 0161-5890
DT Journal
LA English
AB Identification of CTL epitopes for tumor-specific responses is important for the development of immunotherapies to **treat** cancer patients. We have developed a strategy to identify potential CTL epitopes based on screening of sequences of target proteins for presence of specific motifs recognized by the most common HLA-A alleles, and identification of high affinity binding peptides using in vitro quant. assays. A systematic anal. using the sequence of the product of the tumor-assocd. MAGE-1 gene has been carried out. All possible peptides of nine and ten residues, contg. binding motifs for HLA-A1, -A2.1, A-3.2, -A11 and -A24 were synthesized and tested for binding using a quant. assay. Out of 237 possible peptide/MHC combinations, 47 cases demonstrated good binding affinity (Kd .ltoreq. 500 nM). Several peptides were identified as good MHC binders for each one of the five HLA-A alleles studied (five for HLA-A1, 11 for HLA-A2.1, 10 for HLA-A3.2, 16 for HLA-A11 and five for HLA-A24). Furthermore, eight of these peptides were found to bind well to more than one HLA-A allele. These results have important implications for the development of immunotherapeutic vaccines to **treat** malignant melanoma.
IT Lymphocyte
(**T-cell**, cytotoxic, potential melanoma-specific CTL epitopes of tumor-assocd. antigen MAGE-1 for five common HLA-A alleles)
IT 144449-86-5P 154652-80-9P 160213-09-2P 160213-10-5P 160213-11-6P
**160213-14-9P** 160213-16-1P 160213-26-3P 160213-27-4P
160213-29-6P **160213-30-9P** 160213-31-0P 160213-32-1P
160215-85-0P 160567-27-1P 160567-28-2P 160567-29-3P 160567-30-6P
160567-31-7P 160567-32-8P **160567-33-9P** 160567-34-0P
160567-35-1P 160567-36-2P 160567-37-3P 160567-38-4P 160567-39-5P
160567-40-8P 160567-41-9P 160567-42-0P 160567-43-1P 160567-44-2P
160567-45-3P 160567-46-4P 160567-47-5P 160567-48-6P 160567-49-7P
160567-50-0P 160567-51-1P **160567-52-2P** 160567-53-3P
160567-54-4P 160567-55-5P 160567-56-6P 160567-57-7P 160567-58-8P
**160567-59-9P** 160567-60-2P 160567-61-3P 160567-62-4P
160567-63-5P 160567-64-6P 160567-65-7P 160567-66-8P
**160567-67-9P** 160567-68-0P **160567-69-1P** 160567-70-4P
160567-71-5P **160567-72-6P** 160567-73-7P
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(potential melanoma-specific CTL epitopes of tumor-assocd. antigen MAGE-1 for five common HLA-A alleles)
IT **160213-14-9P 160213-30-9P 160567-33-9P**
**160567-52-2P 160567-59-9P 160567-67-9P**

**160567-69-1P 160567-72-6P**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(potential melanoma-specific CTL epitopes of tumor-assocd. antigen MAGE-1 for five common HLA-A alleles)
RN 160213-14-9 CAPLUS
CN L-Leucine,
N-[N-[N-[N-[N-[N-[N-[N-(N-L-lysyl-L-valyl)-L-alanyl]-L-.alpha.-aspartyl]-L-leucyl]-L-valyl]glycyl]-L-phenylalanyl]-L-leucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 160213-30-9 CAPLUS
CN L-Valine, N-[N2-[N-[N-[N-[N-[N-(N-L-lysyl-L-valyl)-L-leucyl]-L-.alpha.-glutamyl]-L-tyrosyl]-L-valyl]-L-isoleucyl]-L-lysyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160567-33-9 CAPLUS
CN L-Lysine, L-alanyl-L-.alpha.-aspartyl-L-leucyl-L-valylglycyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 160567-52-2 CAPLUS
CN L-Isoleucine,
L-seryl-L-tyrosyl-L-valyl-L-lysyl-L-valyl-L-leucyl-L-.alpha.-
glutamyl-L-tyrosyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 160567-59-9 CAPLUS
CN L-Leucine,
N-[N-[N-[N-[N-[N-[N-(N-L-valyl-L-alanyl)-L-.alpha.-aspartyl]-L-leucyl]-L-valyl]glycyl]-L-phenylalanyl]-L-leucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160567-67-9 CAPLUS
CN L-Tyrosine, N-[N2-[N-[N-[N-[N-[N-[N-(N-L-.alpha.-aspartyl-L-leucyl)-L-valyl]glycyl]-L-phenylalanyl]-L-leucyl]-L-leucyl]-L-leucyl]-L-lysyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 160567-69-1 CAPLUS
CN L-Lysine, L-.alpha.-aspartyl-L-leucyl-L-valylglycyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 160567-72-6 CAPLUS
CN L-Lysine,
N2-[N-[N-[N-[N-[N-[N2-(N-L-tyrosyl-L-valyl)-L-lysyl]-L-valyl]-
L-leucyl]-L-.alpha.-glutamyl]-L-tyrosyl]-L-valyl]-L-isoleucyl]- (9CI)
(CA
INDEX NAME)

Absolute stereochemistry.